Lineage Cell Therapeutics (LCTX) Free Cash Flow (2010 - 2026)

Lineage Cell Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 63.21% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$22.6 million, a 1.0% increase from a year earlier, with the FY2025 full-year figure at -$19.4 million, up 17.82% from the prior year.
• Free Cash Flow fell to -$8.1 million in Q1 2026 per LCTX's latest filing, from -$5.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $21.9 million in Q1 2022 and bottomed at -$11.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$5.8 million (2022), against an average of -$4.7 million.
• Across the five-year window, Free Cash Flow surged 393.99% in 2022 and sank 152.13% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$7.9 million in 2022, then rose by 22.68% to -$6.1 million in 2023, then fell by 12.93% to -$6.9 million in 2024, then gained by 22.1% to -$5.4 million in 2025, then tumbled by 51.31% to -$8.1 million in 2026.
• Per Business Quant, the three latest LCTX Free Cash Flow figures stand at -$8.1 million (Q1 2026), -$5.4 million (Q4 2025), and -$3.5 million (Q3 2025).